Lv41
458 积分 2024-05-07 加入
Characteristics and outcomes of patients with HCC treated with atezolizumab/bevacizumab, stratified by second line therapy
8分钟前
求助中
Systemic therapy sequence and outcomes in unresectable hepatocellular carcinoma: results from the multicenter Tokai Post ICI Sequential Therapy Registry cohort
11分钟前
待确认
Clinical characteristics and outcomes of candidates for second-line therapy, including regorafenib and ramucirumab, for advanced hepatocellular carcinoma after sorafenib treatment
13分钟前
已完结
Clinical outcomes of sorafenib treatment failure for advanced hepatocellular carcinoma and candidates for regorafenib treatment in real‐world practice
4小时前
已完结
Analysis of the liver functional reserve of patients with advanced hepatocellular carcinoma undergoing sorafenib treatment: Prospects for regorafenib therapy
4小时前
已完结
Characteristics of patients with sorafenib-treated advanced hepatocellular carcinoma eligible for second-line treatment
4小时前
已完结
Eligibility for Second-line Therapy in Patients With Advanced Hepatocellular Carcinoma
4小时前
已完结
Impact of Etiology on Efficacy Outcomes with Atezolizumab Plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma: A Multinational Retrospective Analysis in Asia-Pacific
3天前
已完结
Analysis of the liver functional reserve of patients with advanced hepatocellular carcinoma undergoing sorafenib treatment: Prospects for regorafenib therapy
3天前
已完结
Data from Intratumoral Administration of Engineered circRNAs Encoding Cytosine Deaminase–Uracil Phosphoribosyltransferase and IL-15 Elicits Superior Antitumor Efficacy
7天前
已关闭
皖公网安备34019202002308
